Among patients with hereditary high-risk breast cancer, including early-onset breast cancer, familial breast cancer, bilateral breast cancer, triple-negative breast cancer (TNBC) and male breast cancer, PALB2 mutation rates are relatively high. This evidence concerns the gene PALB2 and triple-negative breast carcinoma.